WHEN TO CONSIDER XCOPRI
Are your patients still experiencing seizures?
It may be time to consider XCOPRI


XCOPRI® (CENOBAMATE TABLETS) CV IS INDICATED FOR THE TREATMENT
OF PARTIAL-ONSET SEIZURES IN ADULT PATIENTS1
XCOPRI received FDA-approval in 20201
215,853 prescriptions have been written to date for XCOPRI2*
Flexible, once-daily dosing to take patients through their treatment journey1
MOA
XCOPRI is thought to work via a
multimodal mechanism of action1*


XCOPRI has been shown to reduce repetitive neuronal firing by inhibiting voltage-gated sodium currents, including inhibiting the component of the sodium current1

XCOPRI is also a positive allosteric modulator of the y-aminobutyric acid (GABAA) ion channel1
